The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

Hisato Kawakami, Isamu Okamoto, Kimio Yonesaka, Kunio Okamoto, Kiyoko Shibata, Yume Shinkai, Haruka Sakamoto, Michiko Kitano, Takao Tamura, Kazuto Nishio, Kazuhiko Nakagawa

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

We previously showed that tumor-derived heregulin, a ligand for HER3, is associated with both de novo and acquired resistance to cetuximab. We have now examined whether patritumab, a novel neutralizing monoclonal antibody to HER3, is able to overcome such resistance. Human colorectal cancer (DiFi) cells that are highly sensitive to cetuximab were engineered to stably express heregulin by retroviral infection, and the effects of cetuximab and patritumab on the resulting DiFi-HRG cells were examined. DiFi-HRG cells released substantial amounts of heregulin and showed resistance to cetuximab. Cetuximab alone inhibited EGFR and ERK phosphorylation in DiFi-HRG cells, but it had no effect on the phosphorylation of HER2, HER3, or AKT, suggesting that sustained AKT activation by HER2 and HER3 underlies cetuximab resistance in these cells. In contrast, patritumab in combination with cetuximab markedly inhibited the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. The combination therapy also inhibited the growth of DiFi-HRG tumor xenografts in nude mice to a greater extent than did treatment with either drug alone. Activation of HER2- HER3 signaling associated with the operation of a heregulin autocrine loop confers resistance to cetuximab, and patritumab is able to restore cetuximab sensitivity through inhibition of heregulin-induced HER3 activation.

Original languageEnglish
Pages (from-to)11847-11856
Number of pages10
JournalOncotarget
Volume5
Issue number23
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Neuregulin-1
Anti-Idiotypic Antibodies
Colorectal Neoplasms
Phosphorylation
Cetuximab
U3-1287
Neutralizing Antibodies
Heterografts
Nude Mice
Neoplasms
Monoclonal Antibodies
Ligands

All Science Journal Classification (ASJC) codes

  • Oncology

Cite this

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. / Kawakami, Hisato; Okamoto, Isamu; Yonesaka, Kimio; Okamoto, Kunio; Shibata, Kiyoko; Shinkai, Yume; Sakamoto, Haruka; Kitano, Michiko; Tamura, Takao; Nishio, Kazuto; Nakagawa, Kazuhiko.

In: Oncotarget, Vol. 5, No. 23, 01.01.2014, p. 11847-11856.

Research output: Contribution to journalArticle

Kawakami, H, Okamoto, I, Yonesaka, K, Okamoto, K, Shibata, K, Shinkai, Y, Sakamoto, H, Kitano, M, Tamura, T, Nishio, K & Nakagawa, K 2014, 'The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells', Oncotarget, vol. 5, no. 23, pp. 11847-11856. https://doi.org/10.18632/oncotarget.2663
Kawakami, Hisato ; Okamoto, Isamu ; Yonesaka, Kimio ; Okamoto, Kunio ; Shibata, Kiyoko ; Shinkai, Yume ; Sakamoto, Haruka ; Kitano, Michiko ; Tamura, Takao ; Nishio, Kazuto ; Nakagawa, Kazuhiko. / The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells. In: Oncotarget. 2014 ; Vol. 5, No. 23. pp. 11847-11856.
@article{089524ebf20b44e082846a4f3aba5992,
title = "The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells",
abstract = "We previously showed that tumor-derived heregulin, a ligand for HER3, is associated with both de novo and acquired resistance to cetuximab. We have now examined whether patritumab, a novel neutralizing monoclonal antibody to HER3, is able to overcome such resistance. Human colorectal cancer (DiFi) cells that are highly sensitive to cetuximab were engineered to stably express heregulin by retroviral infection, and the effects of cetuximab and patritumab on the resulting DiFi-HRG cells were examined. DiFi-HRG cells released substantial amounts of heregulin and showed resistance to cetuximab. Cetuximab alone inhibited EGFR and ERK phosphorylation in DiFi-HRG cells, but it had no effect on the phosphorylation of HER2, HER3, or AKT, suggesting that sustained AKT activation by HER2 and HER3 underlies cetuximab resistance in these cells. In contrast, patritumab in combination with cetuximab markedly inhibited the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. The combination therapy also inhibited the growth of DiFi-HRG tumor xenografts in nude mice to a greater extent than did treatment with either drug alone. Activation of HER2- HER3 signaling associated with the operation of a heregulin autocrine loop confers resistance to cetuximab, and patritumab is able to restore cetuximab sensitivity through inhibition of heregulin-induced HER3 activation.",
author = "Hisato Kawakami and Isamu Okamoto and Kimio Yonesaka and Kunio Okamoto and Kiyoko Shibata and Yume Shinkai and Haruka Sakamoto and Michiko Kitano and Takao Tamura and Kazuto Nishio and Kazuhiko Nakagawa",
year = "2014",
month = "1",
day = "1",
doi = "10.18632/oncotarget.2663",
language = "English",
volume = "5",
pages = "11847--11856",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "23",

}

TY - JOUR

T1 - The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells

AU - Kawakami, Hisato

AU - Okamoto, Isamu

AU - Yonesaka, Kimio

AU - Okamoto, Kunio

AU - Shibata, Kiyoko

AU - Shinkai, Yume

AU - Sakamoto, Haruka

AU - Kitano, Michiko

AU - Tamura, Takao

AU - Nishio, Kazuto

AU - Nakagawa, Kazuhiko

PY - 2014/1/1

Y1 - 2014/1/1

N2 - We previously showed that tumor-derived heregulin, a ligand for HER3, is associated with both de novo and acquired resistance to cetuximab. We have now examined whether patritumab, a novel neutralizing monoclonal antibody to HER3, is able to overcome such resistance. Human colorectal cancer (DiFi) cells that are highly sensitive to cetuximab were engineered to stably express heregulin by retroviral infection, and the effects of cetuximab and patritumab on the resulting DiFi-HRG cells were examined. DiFi-HRG cells released substantial amounts of heregulin and showed resistance to cetuximab. Cetuximab alone inhibited EGFR and ERK phosphorylation in DiFi-HRG cells, but it had no effect on the phosphorylation of HER2, HER3, or AKT, suggesting that sustained AKT activation by HER2 and HER3 underlies cetuximab resistance in these cells. In contrast, patritumab in combination with cetuximab markedly inhibited the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. The combination therapy also inhibited the growth of DiFi-HRG tumor xenografts in nude mice to a greater extent than did treatment with either drug alone. Activation of HER2- HER3 signaling associated with the operation of a heregulin autocrine loop confers resistance to cetuximab, and patritumab is able to restore cetuximab sensitivity through inhibition of heregulin-induced HER3 activation.

AB - We previously showed that tumor-derived heregulin, a ligand for HER3, is associated with both de novo and acquired resistance to cetuximab. We have now examined whether patritumab, a novel neutralizing monoclonal antibody to HER3, is able to overcome such resistance. Human colorectal cancer (DiFi) cells that are highly sensitive to cetuximab were engineered to stably express heregulin by retroviral infection, and the effects of cetuximab and patritumab on the resulting DiFi-HRG cells were examined. DiFi-HRG cells released substantial amounts of heregulin and showed resistance to cetuximab. Cetuximab alone inhibited EGFR and ERK phosphorylation in DiFi-HRG cells, but it had no effect on the phosphorylation of HER2, HER3, or AKT, suggesting that sustained AKT activation by HER2 and HER3 underlies cetuximab resistance in these cells. In contrast, patritumab in combination with cetuximab markedly inhibited the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. The combination therapy also inhibited the growth of DiFi-HRG tumor xenografts in nude mice to a greater extent than did treatment with either drug alone. Activation of HER2- HER3 signaling associated with the operation of a heregulin autocrine loop confers resistance to cetuximab, and patritumab is able to restore cetuximab sensitivity through inhibition of heregulin-induced HER3 activation.

UR - http://www.scopus.com/inward/record.url?scp=84919964289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84919964289&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.2663

DO - 10.18632/oncotarget.2663

M3 - Article

C2 - 25474137

AN - SCOPUS:84919964289

VL - 5

SP - 11847

EP - 11856

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 23

ER -